Congrats Dr. Neeja Patel (UCLA Health) for leading this important review, out now in AJPC !

Nikita Mittal Pam R. Taub, MD❤️💃🏻 UC San Diego Health

Karol Watson Erin D. Michos, M.D. Dr. Martha Gulati ♥️🫀❤️‍🩹🇨🇦

Unique Features of Dyslipidemia in Women Across a Lifetime and a Tailo... sciencedirect.com/science/articl…

Fantastic presentation by Erika. Thanks to all of our collaborators UC San Diego Health Salk Institute , and to Erika for all of her hard work, making this trial possible. American College of Cardiology Satchin Panda Emily Manoogian UC San Diego Cardiology Sadiya Khan Don Lloyd-Jones Erin D. Michos, M.D. Michael D. Shapiro

Late-breaking data on olezarsen, ASO targeting apoCIII American College of Cardiology #ACC24 Note effects on TGs, non-HDL-C, apoB and safety profile. TIMI Study Group Ionis Sam Tsimikas, MD Brian Bergmark Dan Soffer Christie Ballantyne National Lipid Association

Great session American College of Cardiology #ACC2024 on diet/lifestyle, including these 2 very engaging debates by Pam R. Taub, MD❤️💃🏻 Karen Aspry Carol Kirkpatrick, PhD, MPH, RDN, CLS, FNLA Iulia Iatan, MD PhD #TRE #IF #lowcarb #keto

National Lipid Association Rob Ostfeld, MD, MSc Erin D. Michos, M.D. Eugenia Gianos MD Satchin Panda Emily Manoogian

We are ready for #ACC24 ! Come check out the presentations by UC San Diego Cardiology. American College of Cardiology UC San Diego Cardiology Fellows

With #ACC24 coming up, I will take a deep dive into the new National Lipid Association statement on Lp(a) section by section #KnowLpa

lipid.org/nla/focused-up…

Now Available! The NLA's Scientific Statement: A Focused Update to the 2019 Scientific Statement on Use of Lipoprotein(a) in Clinical Practice. Read the Statement and access the infographic here: ow.ly/MfiZ50R5E53
Marlys Koschinsky Christie Ballantyne Dan Soffer

A focused update to the 2019 NLA scientific statement on use of lipopr... sciencedirect.com/science/articl…. Updated guidance - Measured Lp(a) at least once in all adults! National Lipid Association Marlys Koschinsky Michael Boffa Dave Dixon, Professor & Chair @VCUPharmacy Keith C. Ferdinand, MD, FACC, FAHA, FNLA Erin D. Michos, M.D. Dan Soffer

In response to the misleading claims about TRE last week, I and 33 other international experts wrote a public letter to highlight the critical flaws in the un-peer-reviewed data that received so much attention. You can read our response here: drive.google.com/file/d/1sMUMe-…

Very nicely done article with comments from Pam R. Taub, MD❤️💃🏻 and Don Lloyd-Jones putting this recent controversial AHA Science abstract into context.
Emily Manoogian Satchin Panda

Intermittent Fasting Study Sparks Debate Over Increases in CV Mortality tctmd.com/news/intermitt…

1 - get your Lp(a) checked
2 - if elevated, see a physician who is well versed in Lp(a)
3 - elevated Lp(a) is actionable today!

#KnowLpa

🚨Today is Lp(a) Awareness Day!
Let's use our voices to shed light on the significance of Lp(a) testing. Early detection can be pivotal in preventing cardiovascular diseases. Join us in ensuring everyone knows why it's crucial to #KnowLpa Family Heart Foundation
ow.ly/3CSf50R0ssI

Thank you The New York Times for highlighting today the problems about the recent AHA Science intermittent fasting abstract. We are getting more insights into the actual data. As pointed out by Sameer Bansilal MD, MS there were 31 cardiovascular events in a total of 414 individuals in the <8 hour…

BREAKING

Substantial amounts of high quality randomized clinical trial data demonstrate improved heart outcomes with intermittent fasting.

One of the world's experts in the area, Dr. Pam Taub, discusses the substantial shortcomings of observational nutritional data that the…

We have been burned in medicine so many times by researchers and the press making big assumptions about retrospective data. Here is another example: researchers looked at 2 days' worth of dietary recall data and, based on the duration of food consumption, have made the conclusion…

👉Harnessing RNA Interference for Cholesterol Lowering: The Bench‐to‐Bedside Story of Inclisiran

☝️In 2021, <20 years after the discovery of PCSK9, inclisiran became the first RNA interference therapeutic approved in the United States for LDL‐C lowering in patients with…

Thanks Sam Tsimikas, MD for highlighting our poster, and congrats to Donya Mazdeyasnan MS2 UC San Diego School of Medicine for leading this

AHA Science
UC San Diego Cardiology Harpreet Bhatia Pam R. Taub, MD❤️💃🏻 Erin D. Michos, M.D. Michael D. Shapiro Christie Ballantyne Dr. Michael Garshick Eugenia Gianos MD Lori Daniels

🧠No impact on cognitive function during longer-term use of evolocumab (~75% on background statin). Useful for conversations with patients to reassure intensive LDL-C lowering is safe.

Robert Giugliano Michelle O'Donoghue TIMI Study Group AHA Science Pam R. Taub, MD❤️💃🏻 Erin D. Michos, M.D. Michael D. Shapiro

Expanding field of RNA therapeutics to lower Lp(a), great to see these late-breaking data on lepodisiran, with discussion by Michelle O'Donoghue

AHA Science Steve Nicholls Pam R. Taub, MD❤️💃🏻 Karol Watson Sam Tsimikas, MD Harpreet Bhatia Calvin Yeang MD, PhD Christie Ballantyne Marlys Koschinsky Michael D. Shapiro

⭐️Exciting data for CRISPR base editing targeting PCSK9 to lower LDL-C in familial hypercholesterolemia, with discussion by Dr. Anne Goldberg

AHA Science Foundation of the NLA National Lipid Association Pam R. Taub, MD❤️💃🏻 Karol Watson Erin D. Michos, M.D. Michael D. Shapiro